Drugs / BB3008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06143007 | Oct 2023 → May 2025 overdue | neoplasm | Broadenbio Ltd., Co. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB3008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06143007 ↗ |
| Route | Oral | “BB3008 tablets will be administered orally once daily (QD).” NCT06143007 ↗ |